Moderna is trading at $231.05, down 5.95%, as investors position ahead of full Phase 3 melanoma-vaccine data for intismeran with Merck, scheduled for October 24.
- The decline follows a sharp run-up.
- Broader risk-off trading, including tech weakness, elevated oil and geopolitical concerns, pressured markets and biotech stocks.
- No new Moderna announcement or regulatory decision was reported for October 22.